問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2025-08-20

鄭景全
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

1Cases

2024-03-01 - 2027-12-31

Phase I

Not yet recruiting
A phase I, first in human (FIH), open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of KY386 in patients with DHX33-positive relapsed/refractory advanced malignant tumors
  • Condition/Disease

    DHX33-positive relapsed/refractory advanced malignant tumors

  • Test Drug

    solution

Participate Sites
2Sites

Recruiting2Sites